🔜 #ELCC26 @myesmo.bsky.social
🔥New horizons in therapeutic targets for thoracic malignancies
☑️ #SMARCA4 #MTAP #Bispecific #Trispecific #ADC
🎙️Chair: Dr. Keith M. Kerr, Dr. Junko Tanizaki
@oncoalert.bsky.social LARVOL #LCSM

See what's to come in the next issue of ASH Clinical News! Below, Dr. Samuelson Bannow previews the March issue, with highlights including articles on #AI within medical education, #cytopenia concerns with #BCMA #bispecific #antibody use, and more: https://ow.ly/pK1i50Yl7R5
#HemeSky #MedSky

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study Statement of SignificanceA unique loop structure-based CD19/CD22 bispecific chimeric antigen receptor (CAR) increases dual-targeting efficacy.The CD19/CD22

Antibody Therapeutics(IF=4.5, Oxford University Press)
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study
academic.oup.com/abt/article/...
#CD19 #CD22 #Bispecific #Antibody #CART

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯🎯A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis
academic.oup.com/abt/advance-...
#Bispecific #Antibody

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎆🎆🎆IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy
academic.oup.com/abt/advance-...
#Bispecific #Antibody

New Article Alert from Antibody Therapeutics(IF=4.5, Oxford University Press)
🔥🔥🔥Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/advance-...
#Bispecific #Multispecific #TcellEngager

New article fully published in our journal: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" by authors from Fudan University in Shanghai, China. Congratulations.

doi.org/10.1093/abt/...

#Bispecific #LightChainSingleDomainAntibody

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att

New article alert: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" from Fudan University.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs #Bispecific

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att

A new paper just reached "corrected proof" stage on our journal @antibodytx.bsky.social titled "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design".

doi.org/10.1093/abt/...

#Antibody #SingleDomainAntibody #Bispecific #OpenAccess

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial - Nature Medicine In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

💪#Power of #bispecifics in #cancer #patient #treatment?
✴️Anti-#PD1 x #LAG3 #bispecific had similar anti-#tumour #efficacy vs anti-#PD1/anti-#CTLA4 #combo but with better #safety #profile
⏲️Time to move #multispecifics vs #macrophages where #monos failed!
www.nature.com/articles/s41...

Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule Statement of Significance: Thirty-six bivalent biparatopic antibodies targeting pairs of nine distinct topographical epitopes distributed over CD30 were de

New Research (2025 Paper): "Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule" from Japan

doi.org/10.1093/abt/...

#CD30 #TNFRSF8 #Biparatopic #Bispecific #Oncology

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Redmond, Washington a...

BMS EGFRxHER3 #bispecific #ADC iza-bren granted FDA #Breakthrough Therapy Designation for previously treated advanced EGFR-mutated NSCLC

news.bms.com/news/details...

💡 New Call for Application: BioMed X & #Servier
are launching the first XSeed Labs research project in Paris-Saclay! Focus: #AI-powered design of #bispecific #antibodies for #cancer #therapy. 🧬 Submit your proposal by August 31 2025: career.bmedx.com/call/2025-XP...

Investigate drug efficacy or dissect signalling pathways inv in cancer & other disorders with high quality, yet inexpensive #ichorbio research grade #biosimilars inc #bispecific conjugated & ADC versions

🔗 www.stratech.co.uk/our-partners...

#pharmacokinetics #drugdiscovery #antibdydrugconjugate

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME AbstractBackground. PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an

🎯 PReferentially expressed Antigen in MElanoma (#PRAME) is a promising #anticancer target. Learn more about a novel #bispecific therapy targeting PRAME+ tumors: 🔗 doi.org/10.1093/imma... (7/8)

ICYMI in Cancer Discovery: Zenocutuzumab, a #HER2 x #HER3 #Bispecific Antibody, Is Effective Therapy for Tumors Driven by #NRG1 Gene Rearrangements - by Alison Schram and colleagues @mskcancercenter.bsky.social doi.org/10.1158/2159...

Check out the Consensus Framework for the Optimal Delivery of Bispecific Antibodies in Multiple Myeloma—a practical guide to support safe and effective implementation of these therapies.

Read it here: ucl.ac.uk/lifesciences...

#myeloma #bispecific

FDA grants accelerated approval to zanidatamab-hrii On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.

I am extremely happy and excited to see that a drug that we developed at Zymeworks was just approved by the FDA.

#biparatopic #bispecific #antibody #Oncology #Immunotherapy #BiparatopicAntibodies #HER2 #InnovationInScience

www.fda.gov/drugs/resour...

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. - Merck.com Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has enter...

A day after $BNTX news, Merck joins the PD1 x VEGF #bispecific race. Facing a threat to Keytruda, $MRK licensed LM-299, a PD1/VEGF bsAb in Ph1 from Chinese biotech LaNova Medicines for $588M upfront & up to $2.7B to acquire exclusive global rights to this immunotherapy
www.merck.com/news/merck-e...

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesti...

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants 🦠🧬💉 www.news-medical.net/news/2024050... #COVID19Research #Bispecific #Antibodies #Omicron #Variants #Vaccine #AntibodyTherapy #Pandemic #ViralNeutralization #SARSCoV2 @biorxivpreprint.bsky.social